Healthcare Market Desk

Gene Therapy Market Size, Company Share Analysis and Forecast 2019-2026

Press release   •   Nov 04, 2019 10:19 EST

The global gene therapy market size is expected to grow from USD 581.49 Million in 2017 to USD 5,840.48 Million by 2026 at a CAGR of 22.07% during the forecast period 2019-2026. Increasing gene therapy innovations for cardiovascular and rare diseases treatment and significant investments in the field of gene-related research and development by various biopharmaceutical companies is increasing competition among market players which in turn is driving the growth in the assessment period.

Genetic disorders occur due to mutations in the gene, which result in incorrect protein production. Gene therapy is used to introduce a healthy gene into damaged cells. Mutated gene disrupts the protein function and with the help of gene therapy, the function of that missing protein can be restored. Gene therapy is exclusively being used by the researchers for the treatment of various diseases such as HIV, Cancer, Parkinson’s disease, hemophilia and even immune deficiencies through various approaches. Increasing funding for R&D activities relating to gene therapy and an increase in awareness regarding gene therapy are the major factors propelling the growth of the market.

Request to Get Free Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/29084

A large number of pipeline molecules in development and increasing gene therapy innovations for cardiovascular and rare diseases treatment are some of the major factors for the growth. Also, growing awareness and acceptance of gene therapy for various disease treatments are favouring the growth of the market. Adverse immune responses may restrict the growth of the market. However, increasing funding from government institutions to support the ongoing research is opening new avenues for the market.

Key players operating in the global gene therapy market are Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myer’s Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, and among others. To enhance their market position in the global gene therapy market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership.

  • For instance in June 2019, Axovant Gene Therapies Ltd. signed a strategic partnership with Yposkesi for the manufacturing and development of gene therapy. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance.
  • For instance, in 2016, GlaxoSmithKline received approval from European drug regulatory authority for drug “Strimvelis” for the treatment of ADA-SCID.
  • For instance, in 2017, Spark Therapeutics, a biotech company received approval from the U.S. Food and Drug Administration (FDA) for a gene therapy called “LUXTURNA”. LUXTURNA is a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Viral vector held the largest market share of 62.47% in 2017

Type of vector segment is divided into viral vector and non-viral vector. The key element of gene therapy is the delivery of a modified gene or functioning gene. Viral vector held the largest market share of 62.47% in 2017. Delivery systems deliver functioning gene to intend cell target through several viruses such as Adeno-associated virus, retrovirus and lentivirus are modified in labs for gene therapy drugs. . Non-viral vectors are delivered to the target cells and are DNA plasmids that are given as naked DNA or in connotation with diverse compounds such as gelatin, liposomes, or polyamine nanospheres.

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29084

The cancer segment is expected to grow with the highest CAGR of 26.14% over the forecast period

Disease Indication segment is classified into cardio vascular diseases, cancer, genetic disorders, neuro disorders, infectious diseases, and others. The cancer segment is dominating the market and is expected to grow with the highest CAGR of 26.14% over the forecast period. This growth can be attributed to high number of pipeline products in the past. Rising prevalence of cancer is also contributing to the growth of the segment. The gene therapy is also being used for the treatment of the infectious diseases and this has increased the growth of the infectious diseases segment in global gene therapy market.

North America region dominated the global gene therapy market and held the largest market share of 58.31% in 2017 where as Asia pacific is expected to attain the highest growth in the forecast period. North America region is expected to dominate the market due to large number of clinical trials conducting in the region and increasing number of gene therapy treatment centers in the region. For instance, in 2018, the U.S government approved USD 3 billion for The National Institutes of Health research funds. Asia pacific is expected to register the highest growth in the forecast period. Rising number of population prone to various chronic diseases and offering better solutions to the patients at lower costs are major factors for the growth. For instance, in 2017, National Cancer Center Japan (NCC) and Toray Industries, Inc. developed a new method that could detect thirteen different cancer types with a single drop of blood.

The report analyzes and forecasts the gene therapy market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global gene therapy market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the gene therapy market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of gene therapy market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The main objective of this report is to aid the user in understanding the market as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing. Meticulous research and analysis were an important part of the report preparation. Those reading the report will be able to get a detailed understanding about the market. Industry experts have verified and checked the data and information that have been taken from credible sources like websites, annual reports of companies, journals, and other resources. In order give the facts and data a pictorial form, diagrams, graphs, pie charts, and other representations have been used. That augments the visual appeal of the report and makes understanding it much easier.

Key financial developments of a particular company and product & company overview are some of the elements that help in acquiring information about top vendors in the market. This particular section has also included a SWOT analysis of the companies featured in the report. This will help the audience in knowing about opportunities, strengths, threats and weaknesses that are facing by the key vendors in the chemical and material industry across the world. As the competitive landscape is the most valuable part of any report, it consists of all the required information for the detailed study of top players functioning in the industries. It is also an interesting part to find how exactly these key manufacturers implement various strategies to secure the top rank in the industry. Such an in-depth information is useful for the new entrants into the industry as they would be able to learn a bit from these key vendors. Similarly, the information provided in the research report will also be valuable for the renowned key players as well, as they come to know the strategies of their counterparts to sustain in the competitive industry.

Market Segmentation:

Global Gene Therapy Market, By Type:

  • Germline Gene Therapy
  • Somatic Gene Therapy

Global Gene Therapy Market, By Type of Vector:

  • Viral Vectors
    • Retrovirus
    • Adenovirus
    • Adeno-associated virus
    • Vaccinia virus
    • Herpes simplex virus
    • Others
  • Non-Viral Vectors
    • Injection of Naked DNA
    • Lipofection
    • Others

Global Gene Therapy Market, By Disease Indication:

  • Cardio Vascular Diseases
  • Infectious Diseases
  • Genetic Disorders
  • Neuro Disorders
  • Cancer
  • Others

Report coverage

  • Analysis Period: 2015 – 2026
  • Base Year: 2018
  • Forecast Data: 2019 – 2026
  • Regional Scope: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • Report Coverage: Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global gene therapy capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026)
  • Focuses on the key gene therapy manufacturers, to study the capacity, production, value, market share and development plans in future
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks
  • To identify significant trends and factors driving or inhibiting the market growth
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29084

Table of Content

1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market attractiveness analysis by type
4.3.2. Market attractiveness analysis by type of vector
4.3.3. Market attractiveness analysis by disease indication
4.3.4. Market attractiveness analysis by region
4.4. Industry Trends

5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Increasing Innovations in the Field of Gene Therapy for Cardiovascular and Rare Diseases Treatment
5.2.2. Growing Awareness about the Ability of Gene Therapy
5.2.3. Increasing Adoption in the Treatment of Several Genetic Disorders Especially Cancer, Heart Diseases, Aids and Cystic Fibrosis
5.2.4. Rise in Incidence Rates of Different Types of Cancers
5.3. Restraints
5.3.1. Adverse Immune Responses Related to Treatment
5.4. Opportunities
5.4.1. High Demand from Emerging Economies
5.4.2. Increase in Products Approval
5.5. Challenges
5.5.1. High Cost Associated with the Treatment

6. Global Gene Therapy Market Analysis and Forecast, By Type
6.1. Segment Overview
6.2. Germline Gene Therapy
6.3. Somatic Gene Therapy

7. Global Gene Therapy Market Analysis and Forecast, By Type of Vector
7.1. Segment Overview
7.2. Viral Vectors
7.2.1. Retrovirus
7.2.2. Adenovirus
7.2.3. Adeno-associated virus
7.2.4. Vaccinia virus
7.2.5. Herpes simplex virus
7.2.6. Others
7.3. Non-Viral Vectors
7.3.1. Injection of Naked DNA
7.3.2. Lipofection
7.3.3. Others

8. Global Gene Therapy Market Analysis and Forecast, By Disease Indication
8.1. Segment Overview
8.2. Cardio Vascular Diseases
8.3. Infectious Diseases
8.4. Genetic Disorders
8.5. Neuro Disorders
8.6. Cancer
8.7. Others

9. Global Gene Therapy Market Analysis and Forecast, By Regional Analysis
9.1. Segment Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. Sweden
9.3.4. Netherlands
9.3.5. U.K.
9.3.6. Italy
9.3.7. Spain
9.3.8. Turkey
9.3.9. Switzerland
9.3.10. Belgium
9.3.11. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. South Korea
9.4.5. Australia
9.4.6. Singapore
9.4.7. Malaysia
9.4.8. Thailand
9.4.9. Indonesia
9.4.10. Philippines
9.4.11. Rest of Asia-Pacific
9.5. South America
9.5.1. Brazil
9.5.2. Argentina
9.5.3. Colombia
9.5.4. Rest of South America
9.6. Middle East and Africa
9.6.1. Saudi Arabia
9.6.2. UAE
9.6.3. Egypt
9.6.4. Nigeria
9.6.5. South Africa
9.6.6. Rest of Middle East and Africa

10. Global Gene Therapy Market-Competitive Landscape
10.1. Overview
10.2. Market Share of Key Players in the Gene Therapy Market
10.2.1. Global Company Market Share
10.2.2. North America Company Market Share
10.2.3. Europe Company Market Share
10.2.4. APAC Company Market Share
10.3. Competitive Situations and Trends
10.3.1. Product Launches and Developments
10.3.2. Partnerships, Collaborations, and Agreements
10.3.3. Mergers & Acquisitions
10.3.4. Expansions

11. Company Profiles
11.1. Spark Therapeutics LLC
11.1.1. Business Overview
11.1.2. Company Snapshot
11.1.3. Company Market Share Analysis
11.1.4. Company Product Portfolio
11.1.5. Recent Developments
11.1.6. SWOT Analysis
11.2. Bluebird Bio
11.2.1. Business Overview
11.2.2. Company Snapshot
11.2.3. Company Market Share Analysis
11.2.4. Company Product Portfolio
11.2.5. Recent Developments
11.2.6. SWOT Analysis
11.3. UniQure N.V.
11.3.1. Business Overview
11.3.2. Company Snapshot
11.3.3. Company Market Share Analysis
11.3.4. Company Product Portfolio
11.3.5. Recent Developments
11.3.6. SWOT Analysis
11.4. Juno Therapeutics
11.4.1. Business Overview
11.4.2. Company Snapshot
11.4.3. Company Market Share Analysis
11.4.4. Company Product Portfolio
11.4.5. Recent Developments
11.4.6. SWOT Analysis
11.5. Chiesi Farmaceutici S.p.A
11.5.1. Business Overview
11.5.2. Company Snapshot
11.5.3. Company Market Share Analysis
11.5.4. Company Product Portfolio
11.5.5. Recent Developments
11.5.6. SWOT Analysis
11.6. GlaxoSmithKline
11.6.1. Business Overview
11.6.2. Company Snapshot
11.6.3. Company Market Share Analysis
11.6.4. Company Product Portfolio
11.6.5. Recent Developments
11.6.6. SWOT Analysis
11.7. Bristol Myer’s Squibb
11.7.1. Business Overview
11.7.2. Company Snapshot
11.7.3. Company Market Share Analysis
11.7.4. Company Product Portfolio
11.7.5. Recent Developments
11.7.6. SWOT Analysis
11.8. Celgene Corporation
11.8.1. Business Overview
11.8.2. Company Snapshot
11.8.3. Company Market Share Analysis
11.8.4. Company Product Portfolio
11.8.5. Recent Developments
11.8.6. SWOT Analysis
11.9. Human Stem Cell Institute
11.9.1. Business Overview
11.9.2. Company Snapshot
11.9.3. Company Market Share Analysis
11.9.4. Company Product Portfolio
11.9.5. Recent Developments
11.9.6. SWOT Analysis
11.10. Voyager Therapeutics
11.10.1. Business Overview
11.10.2. Company Snapshot
11.10.3. Company Market Share Analysis
11.10.4. Company Product Portfolio
11.10.5. Recent Developments
11.10.6. SWOT Analysis
11.11. Shire Plc
11.11.1. Business Overview
11.11.2. Company Snapshot
11.11.3. Company Market Share Analysis
11.11.4. Company Product Portfolio
11.11.5. Recent Developments
11.11.6. SWOT Analysis
11.12. Sangamo Biosciences
11.12.1. Business Overview
11.12.2. Company Snapshot
11.12.3. Company Market Share Analysis
11.12.4. Company Product Portfolio
11.12.5. Recent Developments
11.12.6. SWOT Analysis
11.13. Dimension Therapeutics
11.13.1. Business Overview
11.13.2. Company Snapshot
11.13.3. Company Market Share Analysis
11.13.4. Company Product Portfolio
11.13.5. Recent Developments
11.13.6. SWOT Analysis

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29084